Your browser doesn't support javascript.
loading
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.
Watanabe, Kousuke; Kage, Hidenori; Nagoshi, Saki; Toyama, Kazuhiro; Ohno, Yoshiyuki; Shinozaki-Ushiku, Aya; Nakazaki, Kumi; Suzuki, Hiroshi; Kurokawa, Mineo; Nagase, Takahide.
Afiliação
  • Watanabe K; Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  • Kage H; Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  • Nagoshi S; Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  • Toyama K; Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
  • Ohno Y; Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Japan.
  • Shinozaki-Ushiku A; Department of Pathology, The University of Tokyo, Tokyo, Japan.
  • Nakazaki K; Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
  • Suzuki H; Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Japan.
  • Kurokawa M; Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
  • Nagase T; Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
Case Rep Oncol Med ; 2020: 4201727, 2020.
Article em En | MEDLINE | ID: mdl-32257476
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article